AZD 8999

Drug Profile

AZD 8999

Alternative Names: AZD8999; LAS-190792; MABA long-acting; MABA1; Muscarinic antagonist-beta 2 agonist long acting

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Almirall S.A.
  • Developer Almirall S.A.; AstraZeneca
  • Class Antiasthmatics
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 29 Apr 2016 Discontinued - Phase-I for Asthma in United Kingdom (Inhalation)
  • 29 Apr 2016 Discontinued - Phase-I for Chronic obstructive pulmonary disease in United Kingdom (Inhalation)
  • 03 Nov 2014 AstraZeneca and Almirall complete transaction to transfer rights to Almirall's respiratory franchise, including LAS 190792, to AstraZeneca ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top